Fig. 4
miR-589-5p inhibited HCC cell proliferation and metastasis in vitro and in vivo. a-b. Viability of HCC cells transfected with miR-589-5p mimics (a) or inhibitor (b) measured by CCK-8 assays. c-d. Cellular migratory and invasive capabilities were assessed by transwell assays in HLF and 97H cells transfected with miR-589-5p mimics (c) or inhibitor (d), respectively. e. Image of subcutaneous tumor tissues in miR-589-5p overexpressing group and control group. f-g. The volume (f) and weight (g) of subcutaneous tumor tissues were measured. h. Relative expression levels of Ki67 were observed in subcutaneous tumor tissues by IHC. i. In orthotopic model mice, representative images of the liver of miR-589-5p overexpressing group and control group. j. The size of the largest visible liver nodule was measured. k. Quantifications of visible surface liver metastatic nodules. l. Representative images in HE staining of the liver metastasis of HLF cells. m. qRT-PCR analysis of miR-589-5p expression in HCC tissues and matched adjacent normal tissues(n=44). n. The relative expression of miR-589-5p in 44 paired tissues [log2(T/N)]. o. miR-589-5p was negatively correlated with CCDC183-AS1 expression in 44 cases of HCC tissues measured by qRT-PCR. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001; ns, no significance. N, normal tissue; T, tumor tissue